title: HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection.
abstract: Hepatitis B virus (HBV)-reverse seroconversion (RS) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a frequent late-onset complication in recipients with previous HBV infection. We followed 38 allo-HSCT recipients with previous HBV infection, and conducted posttransplant HB vaccine intervention in 13 recipients. First, we followed the recipients without any intervention (historic control) until 2003; hence, we commenced HB vaccination. Out of the patients who underwent transplantation after 2003, 13 recipients were immunized by a standard three-dose regimen after immunosuppressant cessation (vaccine group), whereas 12 recipients were observed without any intervention (nonvaccine group). Eight of the 13 historic control group recipients and 3 of the 12 nonvaccine group recipients, but none of the 13 vaccine group recipients, suffered HBV-RS. Cumulative risks of HBV-RS at 3 years post-HSCT in the historic control, nonvaccine and vaccine groups were 41%, 39%, and 0% respectively (P=.022). We therefore conclude that intervention with HB vaccines is significantly effective in preventing post-HSCT HBV-RS.
authors.affiliation: Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan. masahiro.onozawa@nifty.ne.jp
authors.forename: Masahiro
authors.initials: M
authors.lastname: Onozawa
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hashino
authors.forename: Stephanie
authors.initials: S
authors.lastname: Darmanin
authors.forename: Kohei
authors.initials: K
authors.lastname: Okada
authors.forename: Rena
authors.initials: R
authors.lastname: Morita
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Takahata
authors.forename: Akio
authors.initials: A
authors.lastname: Shigematsu
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kahata
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kondo
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Imamura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006509:Hepatitis B / Q000150:complications / Q000517:prevention & control*; D017325:Hepatitis B Vaccines; D006515:Hepatitis B virus; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D014184:Transplantation, Homologous; D014611:Vaccination; D014775:Virus Activation
chemical_list: D017325:Hepatitis B Vaccines